Clinical trials of active cancer immunotherapy: Where are the right end points?

Expert Opinion on Investigational Drugs

Volumn 16, Issue 8, 2007, Pages 1137-1141

  Nawrocki, Serguisz ^a   Mackiewicz, Andrzej ^b  

^a ZOZ MSWiA z Warmi sko Mazurskim Centrum Onkologii   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

End points; Immunotherapy; Melanoma; Methodology; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOMODULATING AGENT; INTERLEUKIN 6; MELANOMA VACCINE; PLACEBO;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL BASED GENE THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DNA MODIFICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; EDITORIAL; HUMAN; HUMORAL IMMUNITY; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; UNSPECIFIED SIDE EFFECT;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 34548242820     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.8.1137     Document Type: Editorial

References (14)

1. HOOS A, PARMIANI G, HEGE K et al.: A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. (2007) 30:1-15.
2. MICHAELIS LC, RATAIN MJ: Measuring response in a post-RECIST world: from black and white to shades of grey. Nat. Rev. Cancer (2006) 6:409-414.
3. ROSENBERG SA, YANG JC, RESTIFO N: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. (2004) 10:909-915.
4. MACKIEVACZ A, GORNY A, LACIAK M et al.: Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting IL-6 and soluble interleukin 6 receptor. Hum. Gene Ther. (1995) 6:805-811.
5. NAWROCKI S, MURAWA P, MALICKI J et al.: Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol. Lett. (2000) 15:81-86.
6. BOON T, COULIE PG, VAN DEN EYNDE BJ et al.: Human T cell responses against melanoma. Ann. Rev. Immunol. (2006) 24:175-208.
7. THERASSE P, ARBUCK SG, EISENHAUER EA et al.: New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. (2000) 92:205-216.
8. VON HOFF DD: There are no bad anticancer agents, only bad clinical trial designs - twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin. Cancer Res. (1998) 4:1079-1089.
9. NAGORSEN D, THIEL E: Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin. Cancer Res. (2006) 12:3064-3069.
10. SEYMOUR L: The design of clinical trials for new molecularly targeted compounds: progress and new initiatives. Curr. Pharm. Des. (2002) 8:2279-2284.
11. SCHILSKY RL: End points in cancer clinical trials and drug approval process. Clin. Cancer Res. (2002) 8:935-938.
12. SIMON RM, STEINBERG SM, HAMILTON M et al.: Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J. Clin. Oncol. (2001) 19:1848-1854.
13. SIMON RM: Clinical trial designs for therapeutic cancer vaccines. Cancer Treat. Res. (2005) 123:339-350.
14. RUBINSTEIN LV, KORN EL, FREIDLIN B et al.: Design issues of randomized Phase 11 trials and a proposal for Phase II screening trials. J. Clin. Oncol. (2005) 23:7199-7206.